Targeting a specific enzyme to reduce harmful immune responses during severe infections

Targeting ACOD1 to attenuate innate immune responses to lethal infections

NIH-funded research Ut Southwestern Medical Center · NIH-10894116

This study is looking at how a specific enzyme called ACOD1 affects the body's immune response to infections from certain bacteria, and it hopes to find ways to reduce harmful inflammation in people dealing with these infections.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUt Southwestern Medical Center NIH-funded
Lab location1 site (Dallas, United States)
Project IDNIH-10894116 on NIH RePORTER

What this research studies

This research investigates the role of the enzyme ACOD1 in the body's immune response to infections caused by Gram-negative bacteria. It aims to understand how ACOD1 contributes to inflammation and how inhibiting this enzyme can potentially reduce the severity of immune reactions that can lead to serious health complications. The study will involve both genetic and pharmacological approaches to explore the mechanisms behind ACOD1's function in immune cells. By analyzing patient samples, the research seeks to correlate findings with clinical outcomes in individuals suffering from bacterial infections.

Who could benefit from this research

Good fit: Ideal candidates for this research are hospitalized patients suffering from severe bacterial infections, particularly those caused by Gram-negative bacteria.

Not a fit: Patients with non-bacterial infections or those who do not exhibit severe immune responses may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that mitigate severe immune responses in patients with lethal infections, improving survival rates.

How similar studies have performed: Previous research has shown promising results in targeting immune pathways to manage severe infections, suggesting that this approach may be effective.

Where this research is happening

Dallas, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Anti-Cancer Agents
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.